Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of CD19-CAR T Cells in Richter's Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia

Ohad Benjamini, Avichai Shimoni, MD, Michal Besser, PhD, Noga Shem-Tov, MD, Ivetta Danylesko, MD, Ronit Yerushalmi, MD, Drorit Grizim Merkel, MD, Tamar Tadmor, MD, David Lavie, MD, Riva Fineman, MD, Elad Jacobi, MD, Arnon Nagler, MD, Abraham Avigdor, MD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-138904

Published: 2020

Journal Articles

Repeated Courses of Orally Administered Fecal Microbiota Transplantation for the Treatment of Steroid Resistant and Steroid Dependent Intestinal Acute Graft Vs. Host Disease: A Pilot Study (NCT 03214289)

Roni Shouval, MD PhD, Ilan Youngster, MD MSc, Mika Geva, MD, Adi Eshel, MSc, Ivetta Danylesko, MD, Avichai Shimoni, MD, Katia Beider, Joshua A Fein, Itai Sharon, PhD, Omry Koren, PhD, Arnon Nagler, MD

Blood (2018) 132 (Supplement 1): 2121.

https://doi.org/10.1182/blood-2018-99-110270

Published: 2018

Journal Articles

Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

Ohad Benjamini, MD, Maya Zlotnick, MD, Elena Ribakovsky, MD, Meirav Kedmi, MD, Adrian Duek, MD, Drorit Merkel, MD, Merav Leiba, MD, Ivetta Danylesko, MD, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Avichai Shimoni, MD, Abraham Avigdor, MD, Arnon Nagler, Yulia Volchek, MD

Blood (2016) 128 (22): 5429.

https://doi.org/10.1182/blood.V128.22.5429.5429

Published: 2016

Journal Articles

Objective Measures of Pre-Transplant Physiologic Fitness Are Strong Predictors of Very-Short Term Transplantation Related Mortality

Joshua A Fein, Roni Shouval, MD, Noga Shem-Tov, MD, Ivetta Danylesko, MD, Ronit Yerushalmi, MD, Vered Dulberg, MD, Maya Muchnick, MD, Shalom Hassid, Ramit Mehr, PhD, Avichai Shimoni, MD, Arnon Nagler, MD

Blood (2016) 128 (22): 2205.

https://doi.org/10.1182/blood.V128.22.2205.2205

Published: 2016

Journal Articles

Incidence, Risk Factors, Treatment and Outcome of Isolated Extramedullary Relapse after Allogeneic Stem Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome

Noga Shem-Tov, MD, Francesco Saraceni, MD, Ivetta Danylesko, MD, Ronit Yerushalmi, MD, Arnon Nagler, MD MSc, Avichai Shimoni, MD

Blood (2015) 126 (23): 4346.

https://doi.org/10.1182/blood.V126.23.4346.4346

Published: 2015

Journal Articles

Brentuximab Vedotin in Combination with Donor Lymphocyte Infusion for Patients with Hodgkin Lymphoma Relapsing after Allogeneic Stem Cell Transplantation

Panagiotis Tsirigotis, Ronit Yerushalmi, MD, Kostantinos Gkirkas, Noga Shentov, Ivetta Danylesko, MD, Maria Stamouli, MD, Abraham Avigdor, MD, Mohamad Mohty, MD, Avichai Shimoni, Arnon Nagler, MD MSc

Blood (2015) 126 (23): 4361.

https://doi.org/10.1182/blood.V126.23.4361.4361

Published: 2015

Journal Articles

The Combination of Cyclosporine and Mycophenolate Mofetil Is Less Effective Than Cyclosporine and Methotrexate in the Prevention of Acute Graft-Versus Host Disease after Allogeneic Stem Cell Transplantation from Unrelated Donors

Ronit Yerushalmi, MD, Noga Shem-Tov, MD, Ivetta Danylesko, MD, Arnon Nagler, MD MSc, Avichai Shimoni, MD

Blood (2015) 126 (23): 1942.

https://doi.org/10.1182/blood.V126.23.1942.1942

Published: 2015

Journal Articles

Allogeneic Hematopoietic Stem-Cell Transplantation In AML and MDS Using Myeloablative Versus Reduced Intensity Conditioning: 10 Years Later

Avichai Shimoni, MD, Noga Shem-Tov, MD, Yulia Volchek, MD, Ivetta Danylesko, MD, Ronit Yerushalmi, MD, Arnon Nagler, MD, MSc

Blood (2013) 122 (21): 4635.

https://doi.org/10.1182/blood.V122.21.4635.4635

Published: 2013

Journal Articles

The Use Of Tevagrastim (Biosimilar Filgrastim XMO2) For Hematopoietic Stem Cell Mobilization In HLA Matched Sibling Donors For Allogeneic Stem Cell Transplantation To AML/MDS Patients

Ivetta Danylesko, MD, Rina Sareli, Nira Bloom-Varda, Ronit Yerushalmi, Noga Shem-Tov, MD, Yulia Volchek, MD, Avichai Shimoni, MD, Arnon Nagler, MD, MSc

Blood (2013) 122 (21): 3275.

https://doi.org/10.1182/blood.V122.21.3275.3275

Published: 2013

Journal Articles

Favorable Outcome For Patients With Lymphoid Malignancies Following Allogeneic Stem Cell Transplantation Using Fludarabine Treosulfan, Compared With Other Reduced Intensity Conditioning Regimen

Ronit Yerushalmi, MD, Noga Shem-Tov, MD, Yulia Volchek, MD, Ivetta Danylesko, MD, Abraham Avigdor, MD, Arnon Nagler, MD, MSc, Avichai Shimoni

Blood (2013) 122 (21): 3380.

https://doi.org/10.1182/blood.V122.21.3380.3380

Published: 2013

Journal Articles

Allogeneic Stem-Cell Transplantation for AML and MDS with Tresosulfan Compared with Busulfan-Based Regimens; Reduced Toxicity Vs. Reduced Intensity

Avichai Shimoni, MD, Noga Shem-Tov, MD, Ivetta Danylesko, MD, Yulia Volchek, MD, Ronit Yerushalmi, MD, Arnon Nagler

Blood (2011) 118 (21): 495.

https://doi.org/10.1182/blood.V118.21.495.495

Published: 2011

NARROW

Safety and Efficacy of CD19-CAR T Cells in Richter's Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia

Repeated Courses of Orally Administered Fecal Microbiota Transplantation for the Treatment of Steroid Resistant and Steroid Dependent Intestinal Acute Graft Vs. Host Disease: A Pilot Study (NCT 03214289)

Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

Objective Measures of Pre-Transplant Physiologic Fitness Are Strong Predictors of Very-Short Term Transplantation Related Mortality

Incidence, Risk Factors, Treatment and Outcome of Isolated Extramedullary Relapse after Allogeneic Stem Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome

Brentuximab Vedotin in Combination with Donor Lymphocyte Infusion for Patients with Hodgkin Lymphoma Relapsing after Allogeneic Stem Cell Transplantation

The Combination of Cyclosporine and Mycophenolate Mofetil Is Less Effective Than Cyclosporine and Methotrexate in the Prevention of Acute Graft-Versus Host Disease after Allogeneic Stem Cell Transplantation from Unrelated Donors

Allogeneic Hematopoietic Stem-Cell Transplantation In AML and MDS Using Myeloablative Versus Reduced Intensity Conditioning: 10 Years Later

The Use Of Tevagrastim (Biosimilar Filgrastim XMO2) For Hematopoietic Stem Cell Mobilization In HLA Matched Sibling Donors For Allogeneic Stem Cell Transplantation To AML/MDS Patients

Favorable Outcome For Patients With Lymphoid Malignancies Following Allogeneic Stem Cell Transplantation Using Fludarabine Treosulfan, Compared With Other Reduced Intensity Conditioning Regimen

Allogeneic Stem-Cell Transplantation for AML and MDS with Tresosulfan Compared with Busulfan-Based Regimens; Reduced Toxicity Vs. Reduced Intensity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only